NF1
NF1 (neurofibromin 1) is a large protein that stimulates the GTPase activity of Ras and acts as a negative regulator of the Ras signal transduction pathway. The NF1 gene is linked to neurofibromatosis type 1, juvenile myelomonocytic leukaemia and Watson syndrome. Browse Assay Genie's current range of NF1 research reagents below, or read on for the biology behind the target.
NF1, or neurofibromin, stimulates the GTPase activity of Ras. UniProt notes that NF1 shows greater affinity for Ras GAP but lower specific activity, and that it may be a regulator of Ras activity. In line with this, the NCBI Gene summary describes the NF1 gene product as a negative regulator of the Ras signal transduction pathway. By promoting Ras GTP hydrolysis, neurofibromin helps restrain signalling downstream of Ras.
The human NF1 gene encodes neurofibromin 1, which HGNC places in the armadillo-like helical domain containing and CRAL-TRIO lipid binding domain containing gene groups. UniProt records the protein in the nucleus, including the nucleolus, and at the cell membrane. The mouse and rat orthologues are both named Nf1, so the NF1 protein can be studied in common rodent models. The NCBI Gene summary also reports that alternatively spliced transcript variants encoding different isoforms have been described.
Mutations in the NF1 gene have been linked to neurofibromatosis type 1, juvenile myelomonocytic leukaemia and Watson syndrome. The NF1 mRNA is also subject to RNA editing (CGA>UGA, Arg1306Term), which results in premature translation termination. These features make NF1 a frequent subject in studies of Ras pathway regulation, tumour suppression and inherited disease. Researchers may look for an NF1 antibody or an NF1 ELISA kit when measuring neurofibromin expression in these contexts.
NF1 stimulates Ras GTPase activity and negatively regulates the Ras signal transduction pathway, making it central to studies of Ras control.
Mutations in the NF1 gene have been linked to neurofibromatosis type 1, so neurofibromin is a core target in work on this disorder.
NF1 mutations are linked to juvenile myelomonocytic leukaemia and Watson syndrome, supporting research into how loss of neurofibromin contributes to disease.
NF1 mRNA undergoes RNA editing that creates a premature stop codon, and splice variants encode different isoforms, offering topics for transcript-level study.
NF1 (neurofibromin) stimulates the GTPase activity of Ras. UniProt reports greater affinity for Ras GAP but lower specific activity, and describes it as a possible regulator of Ras activity. NCBI Gene describes it as a negative regulator of the Ras signal transduction pathway.
Yes. The NCBI Gene summary states that alternatively spliced transcript variants encoding different isoforms have been described. The NF1 mRNA is also subject to RNA editing (CGA>UGA, Arg1306Term), which causes premature translation termination.
Mutations in the NF1 gene have been linked to neurofibromatosis type 1, juvenile myelomonocytic leukaemia and Watson syndrome. Mouse and rat both carry an orthologue named Nf1; check the datasheet of any product for its validated reactivity.
Other tumour suppressors and N-prefixed signalling and transcription factor targets with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P21359; product specifications from Assay Genie datasheets.